DCM
KALV

Dupont Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History

Dupont Capital Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-14,353
Closed -$174K – 1365
2020
Q2 		$174K Buy
+14,353
New +$153K ﹤0.01% 1167

Other funds holding KALV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Dupont Capital Management's KALV Position: Q3 2020 in Review

Dupont Capital Management sold out of KalVista Pharmaceuticals (KALV) in Q3 2020, closing a stake of 14,353 shares — an estimated $174K sold.

Dupont Capital Management first reported a position in KALV in Q2 2020 and held it in 1 quarter. The position peaked at $174K in Q2 2020. 63 funds tracked by Wall St. Rank hold KALV as of Q3 2020.

  • Dupont Capital Management reported no remaining KalVista Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Dupont Capital Management sold 14,353 KalVista Pharmaceuticals shares in Q3 2020, an estimated $174K.
  • Dupont Capital Management first reported a position in KalVista Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • Dupont Capital Management's KalVista Pharmaceuticals position peaked at $174K in Q2 2020.
  • 63 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q3 2020.

Based on Dupont Capital Management's 13F filing for Q3 2020, filed 29 Oct 2020.